Medicare GLP-1 Bridge: Who Qualifies for $50 Wegovy, Zepbound and Foundayo (2026)

By Dan Brown · Published September 24, 2026 

For years, the standard answer was that Medicare doesn’t cover weight-loss drugs.

That changed on July 1, 2026. Under a temporary federal program called the Medicare GLP-1 Bridge, eligible people with Medicare drug coverage can get certain GLP-1 medications for $50 a month.

It’s a big deal, but it isn’t “Medicare now covers GLP-1s,” full stop. There are specific eligibility rules, specific products, a paperwork step your prescriber has to handle, and an end date.

Here’s what you need to know, taken from Medicare’s and CMS’s own materials.

Article at a Glance

• What it is: A temporary Medicare program that caps certain GLP-1 weight-management drugs at $50 per monthly fill.
• When: July 1, 2026 through December 31, 2027. What happens after that is not settled.
• Which drugs: Foundayo (tablet), Wegovy (injection or tablet) and Zepbound KwikPen only. Zepbound vials and single-dose pens are not included.
• Who: People enrolled in an eligible Medicare drug plan who meet BMI and health criteria.
• How: Your prescriber sends the prescription, and a prior-authorization form is submitted for approval. There is no appeals process, but a corrected request can be resubmitted.
• The catches: The $50 doesn’t count toward your Part D deductible or out-of-pocket limit, coupons can’t be combined with it, and fills are one month at a time.

Quick Answer: Do I Qualify for the Medicare GLP-1 Bridge?

You may qualify if all of these are true:

1. You’re enrolled in an eligible Medicare drug plan: a standalone Part D plan or a Medicare Advantage plan with drug coverage (most common types qualify).
2. You’re 18 or older.
3. You meet one of the BMI and health combinations below.
4. Your prescriber attests that you’re also following a lifestyle program that includes structured nutrition and physical activity.

The Eligibility Criteria

According to CMS, your prescriber must attest that one of the following applies when therapy starts:

Your prescriber determines and attests to your eligibility. This table helps you prepare for that conversation. It isn’t a self-diagnosis tool.

The exclusions, and why they’re not as bad as they sound

You can’t use the Bridge if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH (a form of fatty liver disease).

That doesn’t necessarily mean you’re shut out of GLP-1 treatment. CMS says those conditions point to regular Part D coverage instead, because GLP-1s have separately approved uses for them.

Coverage and cost then depend on your own plan.

Ask your plan or prescriber which route applies to you.

Which Medicare plans are eligible?

CMS lists standalone Prescription Drug Plans, Medicare Advantage plans with drug coverage (coordinated care plans), Special Needs Plans, employer group plans (EGWPs) and LI NET as eligible plan types.

Not eligible: private fee-for-service plans, PACE, fallback plans and religious fraternal benefit plans.

Not sure what type you have? Call the number on your plan card.

Which Drugs Are Covered?

The Zepbound catch: Many self-pay patients use Zepbound vials from LillyDirect. Vials aren’t covered by the Bridge. If you’re switching into the program, you’d need a KwikPen prescription. Pen needles also aren’t covered.

Compounded GLP-1s are not included. The Bridge covers only these FDA-approved brand-name products.

How to Get the $50 Price: Step by Step

1. Talk to your prescriber. Ask whether a GLP-1 is right for you and whether you meet the Bridge criteria. Your prescriber doesn’t have to be enrolled in Medicare, but they can’t be on Medicare’s “Preclusion List.”
2. Your prescriber sends the prescription to your pharmacy. CMS tells prescribers to send the prescription first and wait for the pharmacy to request prior authorization.
3. The prior-authorization form is submitted. Your prescriber completes the Medicare GLP-1 Bridge form electronically or by fax, attesting to your eligibility.
4. Wait for a decision. CMS says decisions are communicated within 72 hours of submission.
5. Fill it at the pharmacy. Bring your Medicare Number (or the pharmacy can look it up with the last 4 digits of your Social Security number). Pharmacies don’t have to sign up separately, and you pay $50 per monthly fill.

If you’re denied: There’s no formal appeals process. Your prescriber can resubmit with corrected or additional information.

The Fine Print Most Articles Skip

• The $50 doesn’t count toward your Part D deductible or yearly out-of-pocket cap. The Bridge runs outside the normal Part D benefit, through a central processor.
• No coupons or discount cards. CMS says coupons and discount programs can’t be applied to Bridge claims.
• One month at a time. You get a single 28- or 30-day supply per fill. 60- and 90-day fills aren’t available.
• Extra Help (LIS) doesn’t lower it. People with Medicare’s Low-Income Subsidy, who may be used to much smaller copays, still pay the $50 under the Bridge, as NPR reported.
• It’s temporary. The program ends December 31, 2027. NPR reported that a longer-term program may or may not follow in 2028.

Truth or Hype? “Medicare Now Covers GLP-1s for $50”

Partly true.

For people who qualify, $50 a month is a dramatic drop: the same medications run $149 to $449 a month at manufacturer self-pay prices. But it’s a temporary program, limited to specific products, with specific clinical criteria, a prior-authorization step, and costs that don’t count toward your out-of-pocket cap.

“Medicare covers GLP-1s now” is too broad. “Eligible Medicare drug-plan members can get three specific GLP-1 products for $50 a month through 2027” is accurate.

What Happens After December 31, 2027?

Nobody knows yet, and we’d be skeptical of anyone who says otherwise.

This matters because many people treat GLP-1s as long-term medication, and research shows weight regain is common after stopping. (See What happens when you stop taking a GLP-1.)

If you start through the Bridge, it’s worth asking your prescriber now: “If the program ends, what’s our plan?” For comparison, here’s what the same drugs cost without it:

One year on the Bridge is $600. One year at $299/month self-pay is $3,588. See our full breakdown: Foundayo vs. Wegovy Pill: What Each Really Costs.

Questions to Ask Before You Start

1. Do I meet the Bridge criteria, and which one applies to me?
2. Do I have a condition (type 2 diabetes, sleep apnea, MASH) that means I should go through my regular Part D plan instead?
3. Which product makes sense for me: Wegovy (pill or injection), Foundayo, or Zepbound KwikPen?
4. Is my Medicare plan an eligible plan type?
5. What’s the plan if the program ends after 2027?
6. Who handles side effects and dose changes, and how do I reach them?

Bottom Line

The Medicare GLP-1 Bridge is a real opportunity for eligible Medicare members: $50 a month instead of hundreds.

But it’s narrower than the headlines suggest: three specific products, specific clinical criteria, a prior-authorization step, and an end date of December 31, 2027.

If you might qualify, talk to your prescriber, check your plan type, and plan ahead for what comes after the Bridge.

Frequently Asked Questions

How much does Wegovy cost with the Medicare GLP-1 Bridge?

$50 per monthly fill for eligible enrollees, for both the Wegovy injection and the Wegovy pill, through December 31, 2027.

Is Zepbound covered by the Medicare GLP-1 Bridge?

Only the Zepbound KwikPen. Zepbound vials and single-dose pens are not covered.

Can I use the Bridge if I have type 2 diabetes?

No. People with type 2 diabetes, moderate-to-severe obstructive sleep apnea or noncirrhotic MASH aren’t eligible for the Bridge. CMS points those conditions to regular Part D coverage instead, so check with your plan.

Does the $50 count toward my Part D out-of-pocket maximum?

No. The Bridge operates outside the normal Part D benefit, and the $50 copays don’t count toward your deductible or yearly out-of-pocket limit.

Can I get a 90-day supply?

No. The program allows one monthly (28- or 30-day) supply per fill.

Is there an appeal if I’m denied?

There’s no formal appeals process under the Bridge. Your prescriber can resubmit the request with corrected or additional information.

Does it cover compounded semaglutide or tirzepatide?

No. Only the listed FDA-approved brand-name products are covered.

About the author: Dan Brown is the founder of Truth or Hype, an independent consumer-information site that tracks telehealth treatments, provider pricing and health-marketing claims. He is not a medical professional. [Edit as you like.]

Medical note: Truth or Hype provides consumer information, not medical advice. GLP-1 medications require evaluation by a licensed healthcare professional. Program note: Program details were checked September 24, 2026 against CMS and Medicare.gov materials and may change. Confirm with Medicare (1-800-MEDICARE), your plan or your prescriber.

Sources

• • CMS: Medicare GLP-1 Bridge, Information for Providers
  • CMS: Medicare GLP-1 Bridge, Information for Pharmacies
  • NPR: Medicare launches weight loss drug option with $50 copay (May 6, 2026)